Brentuximab Vedotin Alone May Be Feasible for Older Patients With Hodgkin Lymphoma

Share this content:
Brentuximab vedotin monotherapy may provide a frontline treatment option for older patients unable to tolerate conventional therapy.
Brentuximab vedotin monotherapy may provide a frontline treatment option for older patients unable to tolerate conventional therapy.

Brentuximab vedotin monotherapy may provide a frontline treatment option for older patients unable to tolerate conventional combination chemotherapy, a new study published online ahead of print in the journal Blood has shown.1

Because treatment-related toxicity is significant in older patients with Hodgkin lymphoma and comorbidities often limit therapeutic options, researchers sought to evaluate the safety and efficacy of frontline brentuximab vedotin monotherapy in patients 60 years or older.

For the open-label, phase 2 study, researchers enrolled 27 patients. All received the CD30-directed antibody-drug conjugate as frontline therapy.

Results showed that the objective response rate was 92%, with a complete remission rate of 73%. Furthermore, all patients achieved stable disease or better, and all had reduced tumor volume following immunotherapy. Median progression-free survival was 10.5 months (range, 2.6+ to 22.3+) and median overall survival had not yet been reached (range, 4.6+ to 24.9+ months).

RELATED: We Can Treat Hodgkin's Lymphoma Like Melanoma?

In regard to safety, the most common adverse events were peripheral sensory neuropathy (78%), fatigue (44%), and nausea (44%), which were grade 2 or lower for most patients.

Patients with diabetes and/or hypothyroidism were particularly prone to developing peripheral neuropathy; however, these comorbidities were not associated with delayed time to resolution or improvement.

Reference

  1. Forero-Torres A, Holkova B, Goldschmidt J, et al. Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older [published online ahead of print September 16, 2015]. Blood. doi: 10.1182/blood-2015-06-644336.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs